このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

健康な成人におけるジヒドロベルベリンが体組成と代謝健康に及ぼす影響 (DHB)

2026年11月9日 更新者:Nanjing Nutrabuilding Bio-tech Co., Ltd.

健康な成人におけるジヒドロベルベリンサプリメントの身体組成、血糖コントロール、エネルギーレベル、食欲、および気分への影響:無作為化二重盲検プラセボ対照並行群臨床試験

The goal of this clinical trial is to evaluate whether dihydroberberine (DHB) supplementation can improve body composition, blood sugar control, energy levels, appetite, and mood in healthy adults with overweight or mild obesity. The study focuses on men and women aged 35-55 years with a BMI between 27.0 and 33.0 kg/m².

The main questions it aims to answer are:

Does daily DHB supplementation lead to greater reductions in body weight over 12 weeks compared to placebo? Does DHB improve glycemic responses, appetite regulation, energy levels, and mood, both acutely (short-term) and chronically (over 12 weeks)?

Researchers will compare two groups-one receiving DHB (400 mg/day) and the other receiving a placebo-administered as two capsules twice daily for 12 weeks. Participants will:

Attend three in-clinic visits over approximately 14 weeks (including screening, baseline, and week 12 visits) Undergo mixed-meal tolerance tests (MTTs) to assess glucose metabolism, appetite, and energy levels Complete body composition assessments (including DXA scans), blood tests (e.g., glucose, insulin, HbA1c), and mood questionnaires (POMS-2) Be monitored for safety throughout the study

調査の概要

研究の種類

介入

入学 (実際)

120

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Illinois
      • Addison、Illinois、アメリカ、60101
        • Biofortis, Merieux NutriSciences

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

35年~55年 (大人)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

Inclusion Criteria:

  • 35 - 55 years of age (inclusive) at visit 1.
  • BMI ≥ 27.0 - ≤ 33.0 kg/m2.
  • Participant has a score of 7 - 10 on the Vein Access Scale Assessment at visit 1.
  • Non-user or former user (daily use; cessation ≥12 months) of tobacco or nicotine products (e.g., cigarette smoking, vaping, chewing tobacco) within 12 months of visit 1, and has no plans to begin use during the study period.
  • Non-habitual users (i.e., daily or almost daily) of marijuana or hemp products, including CBD/THC products, and willing to abstain from use throughout the study period (topical creams/lotions are allowed).
  • Willing to use personal smart phone with operating system capable of downloading and operating study applications (e.g., FitBit, smart scale, activity watch, etc).
  • Willing to adhere to all study procedures, including lifestyle considerations (see section 6.3), and sign forms providing informed consent to participate in the study and authorization to release relevant protected health information to the Clinical Investigator.

Exclusion Criteria:

  • Extreme dietary habits (e.g., ketogenic, very high protein, very high fiber, vegan/vegetarian) at the discretion of the Clinical Investigator.
  • Individuals undergoing moderate-to-intense activity (e.g., sports/exercise ≥ 5h/wk).
  • Recent weight changes (>4.5 kg ≤ 90 d of visit 1), or current/planned engagement in a weight change program (e.g., weight loss or muscle gain) outside of the researcher-instructed, self-directed Lifestyle Intervention throughout the study period.
  • Abnormal laboratory test results of clinical significance at visit 1, at the discretion of the Clinical Investigator. One re-test will be allowed on a separate day prior to visit 2, for subjects with abnormal laboratory test results.
  • Uncontrolled and/or clinically important pulmonary (including uncontrolled asthma), cardiac (including, but not limited to, atherosclerotic disease, history of myocardial infarction, peripheral arterial disease, stroke), hepatic, renal, endocrine (including Type 1 and Type 2 diabetes mellitus), hematologic, immunologic, neurologic (such as Alzheimer's or Parkinson's disease), psychiatric (including depression and/or anxiety disorders) or biliary disorders. Conditions that are well-controlled or resolved will be assessed by the Clinical Investigator on a case-by-case basis.
  • Clinically important GI condition that would potentially interfere with the evaluation of the study product (e.g., inflammatory bowel disease, irritable bowel syndrome, Crohn's disease, celiac disease, history of surgery for weight loss, gastroparesis, and clinically significant lactose or gluten intolerance or other food or ingredient allergies).
  • Uncontrolled hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg. Stable use (no initiation or change in dose ≤ 90 d of visit 1) of FDA-approved medications for hypertension is allowed.
  • History or presence of cancer in the prior 2 years, except for non-melanoma skin cancer.
  • Signs or symptoms of an active infection of clinical relevance ≤ 5 d of visit 1. The visit may be rescheduled once all signs and symptoms have resolved (at the discretion of the Clinical Investigator) at least 5 d prior to visit 1.
  • Recent use (≤ 6 mo of visit 1) of any prescription anti-hyperglycemic/weight loss medication. This includes, but is not limited to: metformin, insulin, DPP-4 inhibitors, SGLT-2 inhibitors, GLP-1 agonist, GIP agonists, Pioglitazone and Sulfonylureas.
  • Use of any dietary supplement, other than conventional once-daily multivitamin/mineral supplements (within limits of the DRI) ≤ 14 d of visit 1 and throughout the study.
  • Recent history (≤ 12 months visit 1) of alcohol or substance abuse. Alcohol abuse is defined as >14 drinks per week (1 drink = 12 oz beer, 5 oz wine, or 1½ oz distilled spirits).
  • Unstable use (change in dose) of any other prescription medications ≤ 90 d of visit 1, except for medications used PRN (e.g., asthma inhalers, non-drowsy seasonal allergy medications, etc.)
  • Antibiotic use ≤ 90 d of visit 1 and throughout the study period.
  • Regular use (≥ 3 days/week ≤ 30 d of visit 1) of anti-inflammatory medications (e.g., NSAIDs) and throughout the study period.
  • Recent use of oral or injectable steroids, or topical or inhaled steroids (≥ 1500 µg/d) within 30 d of visit 1 and throughout the study period.
  • Exposure to any non-registered drug product ≤ 30 d prior to visit 1.
  • Diagnosed with major affective disorder, or other psychiatric disorder, that required hospitalization ≤ 12 months prior to visit 1.
  • Recent (≤ 90 d of visit 1) endoscopy and/or colonoscopy procedure.
  • Major trauma or any other surgical event ≤ 30 d of visit 1.
  • Currently scheduled, or planning to schedule, an elective surgical procedure during the study.
  • Female who is pregnant, planning to be pregnant during the study period, lactating, or is of childbearing potential and is unwilling to commit to the use of a medically approved form of contraception throughout the study period. Women who become pregnant during the study will be discontinued.

General safety related criteria

  • Known sensitivity, intolerability, or allergy to any of the study products or study foods.
  • Has a condition the Clinical Investigator believes would interfere with his ability to provide informed consent, and comply with the study protocol, which might confound the interpretation of the study results, or put the participant at undue risk.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:他の
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
プラセボコンパレーター:プラセボ

Participants will take 4 placebo capsules daily for 12 consecutive weeks, with 2 capsules taken in the morning and 2 in the evening. Each capsule contains 200 mg of microcrystalline cellulose, an inert substance used as an inactive control.

実験的:Dihydroberberine

Participants will take 4 capsules daily (each containing 100 mg dihydroberberine [DHB] and 100 mg microcrystalline cellulose) orally for 12 consecutive weeks, with 2 capsules taken in the morning and 2 in the evening. The total daily dose of DHB is 400 mg.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Body weight
時間枠:Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)

Body weight will be measured in-clinic at Baseline (Visit 2, Week 0, Day 1) and End of Study (Visit 3, Week 12, Day 84) using a calibrated digital scale under standardized conditions (fasted, light clothing, no shoes).

Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)

二次結果の測定

結果測定
メジャーの説明
時間枠
Plasma Glucose Positive Incremental Area Under the Curve (piAUC)
時間枠:Baseline (Visit 2, Day 1): t=0 to t=120 minutes

Positive incremental Area Under the Curve (piAUC0-120min) of plasma glucose following a Mixed-meal Tolerance Test (MTT) after a single dose of study product.

Baseline (Visit 2, Day 1): t=0 to t=120 minutes
Plasma Glucose Maximum Concentration (Cmax)
時間枠:Baseline (Visit 2, Day 1): t=0 to t=120 minutes

Maximum concentration (Cmax) of plasma glucose following a Mixed-meal Tolerance Test (MTT) after a single dose of study product.

Baseline (Visit 2, Day 1): t=0 to t=120 minutes
Plasma Glucose Time to Maximum Concentration (Tmax)
時間枠:Baseline (Visit 2, Day 1): t=0 to t=120 minutes

Time to maximum concentration (Tmax) of plasma glucose following a Mixed-meal Tolerance Test (MTT) after a single dose of study product.

Baseline (Visit 2, Day 1): t=0 to t=120 minutes
Composite Appetite Score Net Incremental Area Under the Curve (niAUC)
時間枠:Baseline (Visit 2, Day 1): t=0 to t=120 minutes

Net incremental Area Under the Curve (niAUC0-120min) for the Composite Appetite Score following a Mixed-meal Tolerance Test (MTT) after a single dose of study product.

Baseline (Visit 2, Day 1): t=0 to t=120 minutes
Net Incremental Area Under the Curve (niAUC0-120min) for Individual Appetite Visual Analog Scale (VAS) Ratings
時間枠:Baseline (Visit 2, Day 1): t=0 to t=120 minutes

Net incremental area under the curve (niAUC) from 0 to 120 minutes for individual appetite-related sensations measured using a 100-mm Visual Analog Scale (VAS), including Hunger, Desire to Eat, Fullness, and Prospective Food Consumption. The VAS ranges from 0 mm ("not at all") to 100 mm ("extremely"). Higher scores on Hunger, Desire to Eat, and Prospective Food Consumption indicate greater appetite drive and poorer satiety; higher scores on Fullness indicate greater satiety (better outcome).

Baseline (Visit 2, Day 1): t=0 to t=120 minutes
Composite Appetite Score Positive Maximum Response
時間枠:Baseline (Visit 2, Day 1): t=0 to t=120 minutes

Maximum positive change from fasting baseline in the Composite Appetite Score, calculated as the average of standardized 100-mm Visual Analog Scale (VAS) ratings for Hunger, Desire to Eat, Fullness, and Prospective Food Consumption. The VAS ranges from 0 mm ("not at all") to 100 mm ("extremely"). Higher values for Hunger, Desire to Eat, and Prospective Food Consumption reflect increased appetite, while higher values for Fullness reflect enhanced satiety; the composite score is interpreted based on the net direction of these opposing components (better outcome).

Baseline (Visit 2, Day 1): t=0 to t=120 minutes
Individual Appetite Visual Analog Scale (VAS) Ratings Positive Maximum Response
時間枠:Baseline (Visit 2, Day 1): t=0 to t=120 minutes

Maximum positive deviation from fasting baseline in individual appetite-related sensations measured using a 100-mm Visual Analog Scale (VAS) for Hunger, Desire to Eat, Fullness, and Prospective Food Consumption. The scale ranges from 0 mm ("not at all") to 100 mm ("extremely"). Higher scores on Hunger, Desire to Eat, and Prospective Food Consumption represent greater appetite and poorer satiety; higher scores on Fullness represent stronger satiety (better outcome) .

Baseline (Visit 2, Day 1): t=0 to t=120 minutes
Energy Composite Score Net Incremental Area Under the Curve (niAUC)
時間枠:Baseline (Visit 2, Day 1): t=0 to t=120 minutes

Net incremental area under the curve (niAUC) from 0 to 120 minutes for the Energy Composite Score, derived as the mean of three 100-mm Visual Analog Scale (VAS) items: Energy, Vigor, and Pep. Each VAS ranges from 0 mm ("not at all") to 100 mm ("extremely"). Higher scores indicate greater perceived energy levels and are interpreted as a better outcome.

Baseline (Visit 2, Day 1): t=0 to t=120 minutes
Energy Composite Score Positive Maximum Response
時間枠:Baseline (Visit 2, Day 1): t=0 to t=120 minutes

Maximum positive change from fasting baseline in the Energy Composite Score, calculated as the average of three 100-mm Visual Analog Scale (VAS) ratings: Energy, Vigor, and Pep. The VAS ranges from 0 mm ("not at all") to 100 mm ("extremely"). Higher scores reflect greater increases in subjective energy and are considered a better outcome.

Baseline (Visit 2, Day 1): t=0 to t=120 minutes
Fatigue Composite Score Net Incremental Area Under the Curve (niAUC)
時間枠:Baseline (Visit 2, Day 1): t=0 to t=120 minutes

Net incremental area under the curve (niAUC) from 0 to 120 minutes for the Fatigue Composite Score, calculated as the mean of three 100-mm Visual Analog Scale (VAS) items: Fatigue, Exhaustion, and Worn-out. Each VAS ranges from 0 mm ("not at all") to 100 mm ("extremely"). Higher scores indicate greater perceived fatigue and are interpreted as a worse outcome.

Baseline (Visit 2, Day 1): t=0 to t=120 minutes
Fatigue Composite Score Positive Maximum Response
時間枠:Baseline (Visit 2, Day 1): t=0 to t=120 minutes

Maximum positive change from fasting baseline in the Fatigue Composite Score, derived from the average of three 100-mm Visual Analog Scale (VAS) ratings: Fatigue, Exhaustion, and Worn-out. The VAS ranges from 0 mm ("not at all") to 100 mm ("extremely"). Higher scores reflect greater increases in perceived fatigue and are considered a worse outcome.

Baseline (Visit 2, Day 1): t=0 to t=120 minutes
Waist Circumference (WC)
時間枠:Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)

Change in in-clinic measured Waist Circumference from Baseline to the End of the Study.

Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)
Hip Circumference (HC)
時間枠:Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)

Change in in-clinic measured Hip Circumference from Baseline to the End of the Study.

Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)
Waist-to-Hip Ratio (WHR)
時間枠:Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)

Change in calculated Waist-to-Hip Ratio (WC/HC) from Baseline to the End of the Study.

Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)
Lean Mass
時間枠:Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)

Change in total and regional (arms, legs, trunk) lean mass, measured via Dual-energy X-ray Absorptiometry (DXA), from Baseline to the End of the Study.

Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)
Fat Mass
時間枠:Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)

Change in total and regional (arms, legs, trunk) fat mass, measured via DXA, from Baseline to the End of the Study.

Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)
Fat-Free Mass
時間枠:Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)

Change in total fat-free mass, measured via DXA, from Baseline to the End of the Study.

Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)
Visceral Adipose Tissue (VAT)
時間枠:Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)

Change in abdominal visceral fat mass and volume, measured via DXA, from Baseline to the End of the Study.

Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)
Fasting Plasma Glucose
時間枠:Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)

Change in fasting plasma glucose levels from Baseline to the End of the Study.

Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)
Fasting Plasma Insulin
時間枠:Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)

Change in fasting plasma insulin levels from Baseline to the End of the Study.

Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)
Glycated Hemoglobin (HbA1c)
時間枠:Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)

Change in Glycated Hemoglobin (HbA1c) levels from Baseline to the End of the Study.

Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)
Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)
時間枠:Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)

Change in HOMA-IR calculated from fasting glucose and insulin levels from Baseline to the End of the Study.

Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)
Fasting Plasma Leptin
時間枠:Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)

Change in fasting plasma leptin levels from Baseline to the End of the Study.

Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)
Postprandial Glucose niAUC (0-120 min)
時間枠:Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)

Change in postprandial glucose niAUC (0-120 min) response to an MTT from Baseline to the End of the Study.

Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)
Postprandial Glucose Cmax
時間枠:Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)

Change in postprandial glucose Cmax response to an MTT from Baseline to the End of the Study.

Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)
Postprandial Glucose Tmax
時間枠:Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)

Change in postprandial glucose Tmax response to an MTT from Baseline to the End of the Study.

Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)
Postprandial Appetite Visual Analog Scale (VAS) Net Incremental Area Under the Curve (niAUC; 0-120 minutes)
時間枠:Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)

Change from baseline to end of study in the net incremental area under the curve (niAUC) over 0 to 120 minutes for postprandial appetite ratings measured using a 100-mm Visual Analog Scale (VAS), including Hunger, Desire to Eat, Fullness, and Prospective Food Consumption. The VAS ranges from 0 mm ("not at all") to 100 mm ("extremely"). Higher scores on Hunger, Desire to Eat, and Prospective Food Consumption indicate greater appetite drive and poorer satiety ; higher scores on Fullness indicate greater satiety (better outcome).

Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)
Postprandial Appetite Visual Analog Scale (VAS) Positive Maximum Response
時間枠:Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)

Change from baseline to end of study in the positive maximum response (maximum increase from fasting value) of postprandial appetite ratings measured using a 100-mm Visual Analog Scale (VAS), including Hunger, Desire to Eat, Fullness, and Prospective Food Consumption. The VAS ranges from 0 mm ("not at all") to 100 mm ("extremely"). Higher scores on Hunger, Desire to Eat, and Prospective Food Consumption indicate greater appetite drive and poorer satiety; higher scores on Fullness indicate greater satiety (better outcome).

Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)
Postprandial Energy Visual Analog Scale (VAS) Net Incremental Area Under the Curve (niAUC; 0-120 min)
時間枠:Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)

Change from baseline to end of study in the net incremental area under the curve (niAUC) over 0-120 minutes for postprandial energy-related ratings measured using a 100-mm Visual Analog Scale (VAS), including Energy, Vigor, and Pep. The VAS ranges from 0 mm ("not at all") to 100 mm ("extremely"). Higher niAUC values indicate greater postprandial energy enhancement and are interpreted as a better outcome.

Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)
Postprandial Energy Visual Analog Scale (VAS) Positive Maximum Response
時間枠:Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)

Change from baseline (Week 0) to end of study (Week 12) in the incremental peak response (defined as the maximum increase from the pre-meal fasting value) for postprandial energy-related ratings. Ratings are assessed using a 100-mm Visual Analog Scale (VAS) for three items: Energy, Vigor, and Pep. The VAS ranges from 0 mm ("not at all") to 100 mm ("extremely"). Higher scores represent a greater maximal increase in perceived energy levels, indicating a better outcome.

Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)
Profile of Mood States -2 (POMS-2) Total and Component Scores
時間枠:Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)

Change from baseline to end of study in the POMS-2 Total Mood Disturbance (TMD) score and six component subscale scores: Anger-Hostility, Confusion-Bewilderment, Depression-Dejection, Fatigue-Inertia, Tension-Anxiety, and Vigor-Activity. The POMS-2 is a validated 65-item self-report questionnaire rated on a 5-point Likert scale (0 = "Not at all" to 4 = "Extremely"). The TMD score is calculated by summing the scores of the five negative mood subscales and subtracting the Vigor-Activity score. Higher TMD and negative subscale scores reflect greater emotional distress (worse outcome), while higher Vigor-Activity scores reflect increased energy and well-being (better outcome).

Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)

その他の成果指標

結果測定
メジャーの説明
時間枠
Number of participants with abnormal Clinical Chemistry Panel (CMP) tests result
時間枠:Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)

Number of participants with CMP analyte values (including albumin, alkaline phosphatase, total bilirubin, direct bilirubin, calcium, chloride, creatinine, BUN, potassium, AST, ALT, sodium, total protein, CO2, and osmolality) that are outside the reference range and considered clinically significant by the investigator.

Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)
Number of participants with abnormal Complete Blood Count (CBC) tests result
時間枠:Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)

Number of participants with CBC analyte values (including WBC, RBC, hemoglobin concentration, hematocrit, MCV, MCH, MCHC, neutrophils, lymphocytes, monocytes, eosinophils, basophils, and platelet count) that are outside the reference range and considered clinically significant by the investigator.

Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)
Blood Pressure
時間枠:Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)

Change in resting systolic blood pressure and diastolic blood pressure from Baseline to the End of the Study.

Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)
Heart Rate
時間枠:Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)

Change in resting heart rate from Baseline to the End of the Study.

Baseline (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)
Adverse Events (AEs) and Serious Adverse Events (SAEs)
時間枠:Start of study product consumption (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)

Incidence, type, severity, and relationship to the study product of AEs and SAEs occurring during the chronic phase.

Start of study product consumption (Visit 2, Week 0, Day 1) to End of the Study (Visit 3, Week 12, Day 84)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年12月15日

一次修了 (実際)

2026年9月18日

研究の完了 (実際)

2026年10月12日

試験登録日

最初に提出

2025年12月12日

QC基準を満たした最初の提出物

2025年12月29日

最初の投稿 (実際)

2026年1月7日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月12日

QC基準を満たした最後の更新が送信されました

2026年11月9日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する